射血分数降低型心力衰竭（HFrEF）治疗的最新进展的循证综述。

An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).

机构信息

Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.

Division of General Internal Medicine & Geriatrics, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.

出版信息

Postgrad Med J. 2016 Dec;92(1094):726-734. doi: 10.1136/postgradmedj-2016-134378. Epub 2016 Oct 5.

DOI:10.1136/postgradmedj-2016-134378

PMID:27708003

Abstract

An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves from either functional or structural changes to the ventricles that lead to filling or ejection abnormalities. Thus far, pharmacotherapy has been show to be beneficial in patients only with reduced ejection fraction; however, new therapies have been developed in hopes of reducing the burden of heart failure. In this review, we will discuss current pharmacotherapies recommended in American College of Cardiology/American Heart Association guidelines, the evidence behind these recommendations as well as new and emerging therapies that have been developed.

摘要

据估计，美国有 510 万慢性心力衰竭患者，到 2030 年，这一数字预计将增加 25%。心力衰竭是一种临床综合征，它是由心室的功能或结构变化引起的充盈或射血异常而发展而来。到目前为止，药物治疗已被证明对射血分数降低的患者有益；然而，为了减轻心力衰竭的负担，已经开发了新的治疗方法。在这篇综述中，我们将讨论美国心脏病学会/美国心脏协会指南中推荐的当前药物治疗方法，这些建议背后的证据以及已经开发出的新的和新兴的治疗方法。